Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer

Kweon Sang Moon; Joo Yeon Ji; Yoo Jin Cho; Jong Hwa Lee; Myung Sup Choi; Euishin Edmund Kim

doi:doi:10.11648/j.jctr.20150303.14

| Peer-Reviewed

Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer

Kweon Sang Moon, Joo Yeon Ji, Yoo Jin Cho, Jong Hwa Lee, Myung Sup Choi, Euishin Edmund Kim

Published in Journal of Cancer Treatment and Research (Volume 3, Issue 3)

Received: 4 March 2015 Accepted: 29 May 2015 Published: 4 July 2015

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of angiogenesis by deoxypodophyllotoxin element as well as c-Met signal pathway inhibition in the pancreatic cancer. We present its therapeutic effect in 50 patients with stage IV pancreatic cancer for the first time in Korea. Materials and Methods From March 2013 to May 2014, there were 50 patients with stage IV pancreatic cancers admitted to Sahmyook Seoul Hospital for SB anticancer treatments with 24 control patient who did not get SB anticancer treatments in the same time interval.SB anticancer drug were administrated directly intratumoral injections using radiofrequent ablation techniques by interventional radiologist and intravenously by physician. Results Total 50 patients received SB anticancer therapy, male 25, female 25, and age ranged from 27 to 86 years with median age of 57 years with liver, lung, peritoneum and/or bone metastases, Control 24 patients, male 10, female 14, age ranged from 36 to 90 years with median age of 69 years. There was no significant side effect clinically as well as by laboratory measurement after every SB injections. Number of survived patients in SB study group was 27cases (54.0%), but only 2 cases(8.3%) in SB not treated control group ( p<0.01 with statistical significance). The total survival duration after diagnosis in SB treated group was 7 months, but 4 months in SB not treated control group. The interval from initial diagnosis to SB treatment in survived group was 2 month, less than 1 month in 12(44.4%) patients while in death group 5 months, and less than 1 month in only 3(14.3%) cases (p< 0.01 with statistical significance).The follow up duration and progression free estimate after SB treatment in survived group was median 5 months each, while in control group, median 2 months. Conclusion: SB natural anticancer drug administration is safe and increases survival rate and duration compared with control group, especially when treated within 1 month after diagnosis of stage IV pancreatic cancer. Long term follow up study with more numbers of patients are needed for accurate efficacy of SB treatment for advanced pancreatic cancer.

Published in	Journal of Cancer Treatment and Research (Volume 3, Issue 3)
DOI	10.11648/j.jctr.20150303.14
Page(s)	42-46
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2015. Published by Science Publishing Group

Keywords

Pancreatic Cancer Stage IV, SB, Natural Anticancer Drug

References

[1]	Li D, Kie K, Wolff R and Abbruzzese JL. Pancreatic cancer. Lancet 2004; 363: 1049-1057
[2]	Burris HJ , Moore MJ, Andersen J, Green MR , Rothenberg ML , Modiano MR, et all. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer :A randomized trial. J Clin Oncol 1997; 15: 2403-2413
[3]	Demols A, Peters M ,Polus M, Marechal R, Gay F, Monsaert E, et all. Gemcitabine and Oxaloplatin(GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study .Br J Cancer 2006; 94: 481-485
[4]	Choi JH , Oh SY , Kwon HC , Kim JH , Lee JH , Lee S, et al. Gemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: A retrospective analysis. Cancer Res Treat 2008; 40: 22-26
[5]	Sudo K,Ishihara T, Hirata N, Ozawa F, Ohshima T, Azemoto R, et al. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemother Pharmacol 2014; 73(2): 389-396
[6]	Renouf DJ , Tang PA , Hedley D, Chen E, Kamel-Reid S, Tsao MS , et all. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Europ J Cancer 2014; 50: 1909-1915
[7]	Wang R, Cheng L, Xia J, Wang Z, Wang Q and Wang Z. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells. Curr Cancer Drug Targets 2014; 14(4): 407-417
[8]	Kang SS . Saponins from the roots of Pulsatilla koreana. Arch. Pharm Res 1989; 12(1): 42-47
[9]	Kim SY and Kim SB . Antitumor effect of extracts of Pulsatilla koreana in vitro. J Korean Cancer Asso 1994; 26(6): 959-963
[10]	Kim Y, Bang SC , Lee J H and Ahn BZ . Pulsatilla saponin D: The antitumor principle from Pulsatilla koreana. Arch Pharm Res 2004; 27: 915-918
[11]	Kim Y , Kim SB , You YJ and Ahn BZ. Deoxypodophyllotoxin; The cytotoxic and antiangiogenic Component from Pulsatilla koreana. Planta Medica 2002; 68: 271-274
[12]	Bang SC , Lee JH , Song GY , Kim DH , Yoon MY and Ahn BZ . Antitumor activity of Pulsatilla koreana saponins and their structure-activity relationship. Chem Pharm Bull 2005; 53: 1451-1454
[13]	Smith M and Boon HS . Counseling cancer patients about herbal medicine. Patient Educ Couns 1999; 38: 109-120
[14]	Son MK , Jung KH , Lee HS , Lee HS , Kim SJ , Yan HH , et al. SB365,Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Oncol Rep 2013; 30: 801-808
[15]	Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18
[16]	Hong S W, Jung KH , Lee HS , Son MK , Yan HH, Kang NS , et al. SB 365 Pulsatilla saponin D,targets c-Met and exerts antiangiogenic and antitumor activities. Carcinogenesis 2013; 34(9): 2156-2169
[17]	Xia C, Heng Q, Cao Z, Shi X and Jiang BH. Regulation of angiogenesis and tumor growth by p110 alpha and AKTI via VEGF expression. J Cell Physiol 2006; 209: 56-66
[18]	Liu X, Yao W, Newton RC and Scherle PA. Targeting the c-Met signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008; 17: 997-1011

Cite This Article

Plain Text BibTeX RIS

APA Style

Kweon Sang Moon, Joo Yeon Ji, Yoo Jin Cho, Jong Hwa Lee, Myung Sup Choi, et al. (2015). Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer. Journal of Cancer Treatment and Research, 3(3), 42-46. https://doi.org/10.11648/j.jctr.20150303.14

Copy | Download

ACS Style

Kweon Sang Moon; Joo Yeon Ji; Yoo Jin Cho; Jong Hwa Lee; Myung Sup Choi, et al. Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer. J. Cancer Treat. Res. 2015, 3(3), 42-46. doi: 10.11648/j.jctr.20150303.14

Copy | Download

AMA Style

Kweon Sang Moon, Joo Yeon Ji, Yoo Jin Cho, Jong Hwa Lee, Myung Sup Choi, et al. Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer. J Cancer Treat Res. 2015;3(3):42-46. doi: 10.11648/j.jctr.20150303.14

Copy | Download

@article{10.11648/j.jctr.20150303.14,
  author = {Kweon Sang Moon and Joo Yeon Ji and Yoo Jin Cho and Jong Hwa Lee and Myung Sup Choi and Euishin Edmund Kim},
  title = {Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer},
  journal = {Journal of Cancer Treatment and Research},
  volume = {3},
  number = {3},
  pages = {42-46},
  doi = {10.11648/j.jctr.20150303.14},
  url = {https://doi.org/10.11648/j.jctr.20150303.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20150303.14},
  abstract = {Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of angiogenesis by deoxypodophyllotoxin element as well as c-Met signal pathway inhibition in the pancreatic cancer. We present its therapeutic effect in 50 patients with stage IV pancreatic cancer for the first time in Korea. Materials and Methods From March 2013 to May 2014, there were 50 patients with stage IV pancreatic cancers admitted to Sahmyook Seoul Hospital for SB anticancer treatments with 24 control patient who did not get SB anticancer treatments in the same time interval.SB anticancer drug were administrated directly intratumoral injections using radiofrequent ablation techniques by interventional radiologist and intravenously by physician. Results Total 50 patients received SB anticancer therapy, male 25, female 25, and age ranged from 27 to 86 years with median age of 57 years with liver, lung, peritoneum and/or bone metastases, Control 24 patients, male 10, female 14, age ranged from 36 to 90 years with median age of 69 years. There was no significant side effect clinically as well as by laboratory measurement after every SB injections. Number of survived patients in SB study group was 27cases (54.0%), but only 2 cases(8.3%) in SB not treated control group ( p<0.01 with statistical significance). The total survival duration after diagnosis in SB treated group was 7 months, but 4 months in SB not treated control group. The interval from initial diagnosis to SB treatment in survived group was 2 month, less than 1 month in 12(44.4%) patients while in death group 5 months, and less than 1 month in only 3(14.3%) cases (p< 0.01 with statistical significance).The follow up duration and progression free estimate after SB treatment in survived group was median 5 months each, while in control group, median 2 months. Conclusion: SB natural anticancer drug administration is safe and increases survival rate and duration compared with control group, especially when treated within 1 month after diagnosis of stage IV pancreatic cancer. Long term follow up study with more numbers of patients are needed for accurate efficacy of SB treatment for advanced pancreatic cancer.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer
AU  - Kweon Sang Moon
AU  - Joo Yeon Ji
AU  - Yoo Jin Cho
AU  - Jong Hwa Lee
AU  - Myung Sup Choi
AU  - Euishin Edmund Kim
Y1  - 2015/07/04
PY  - 2015
N1  - https://doi.org/10.11648/j.jctr.20150303.14
DO  - 10.11648/j.jctr.20150303.14
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 42
EP  - 46
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20150303.14
AB  - Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of angiogenesis by deoxypodophyllotoxin element as well as c-Met signal pathway inhibition in the pancreatic cancer. We present its therapeutic effect in 50 patients with stage IV pancreatic cancer for the first time in Korea. Materials and Methods From March 2013 to May 2014, there were 50 patients with stage IV pancreatic cancers admitted to Sahmyook Seoul Hospital for SB anticancer treatments with 24 control patient who did not get SB anticancer treatments in the same time interval.SB anticancer drug were administrated directly intratumoral injections using radiofrequent ablation techniques by interventional radiologist and intravenously by physician. Results Total 50 patients received SB anticancer therapy, male 25, female 25, and age ranged from 27 to 86 years with median age of 57 years with liver, lung, peritoneum and/or bone metastases, Control 24 patients, male 10, female 14, age ranged from 36 to 90 years with median age of 69 years. There was no significant side effect clinically as well as by laboratory measurement after every SB injections. Number of survived patients in SB study group was 27cases (54.0%), but only 2 cases(8.3%) in SB not treated control group ( p<0.01 with statistical significance). The total survival duration after diagnosis in SB treated group was 7 months, but 4 months in SB not treated control group. The interval from initial diagnosis to SB treatment in survived group was 2 month, less than 1 month in 12(44.4%) patients while in death group 5 months, and less than 1 month in only 3(14.3%) cases (p< 0.01 with statistical significance).The follow up duration and progression free estimate after SB treatment in survived group was median 5 months each, while in control group, median 2 months. Conclusion: SB natural anticancer drug administration is safe and increases survival rate and duration compared with control group, especially when treated within 1 month after diagnosis of stage IV pancreatic cancer. Long term follow up study with more numbers of patients are needed for accurate efficacy of SB treatment for advanced pancreatic cancer.
VL  - 3
IS  - 3
ER  -

Copy | Download

Author Information

Kweon Sang Moon

Department of Surgery, Sahmyook Seoul Hospital, Seoul, Korea
Joo Yeon Ji

Department of Radiology, Sahmyook Seoul Hospital, Seoul, Korea
Yoo Jin Cho

Sahmyook Cancer Center, Sahmyook Seoul Hospital, Seoul, Korea
Jong Hwa Lee

Sahmyook Cancer Center, Sahmyook Seoul Hospital, Seoul, Korea
Myung Sup Choi

Department of Family Medicine, Sahmyook Seoul Hospital, Seoul, Korea
Euishin Edmund Kim

Department of Molecular Medicine, Graduate School of Covergence Science and Technology, Seoul National University, Seoul, Korea

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Kweon Sang Moon, Joo Yeon Ji, Yoo Jin Cho, Jong Hwa Lee, Myung Sup Choi, et al. (2015). Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer. Journal of Cancer Treatment and Research, 3(3), 42-46. https://doi.org/10.11648/j.jctr.20150303.14

Copy | Download

ACS Style

Kweon Sang Moon; Joo Yeon Ji; Yoo Jin Cho; Jong Hwa Lee; Myung Sup Choi, et al. Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer. J. Cancer Treat. Res. 2015, 3(3), 42-46. doi: 10.11648/j.jctr.20150303.14

Copy | Download

AMA Style

Kweon Sang Moon, Joo Yeon Ji, Yoo Jin Cho, Jong Hwa Lee, Myung Sup Choi, et al. Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer. J Cancer Treat Res. 2015;3(3):42-46. doi: 10.11648/j.jctr.20150303.14

Copy | Download

@article{10.11648/j.jctr.20150303.14,
  author = {Kweon Sang Moon and Joo Yeon Ji and Yoo Jin Cho and Jong Hwa Lee and Myung Sup Choi and Euishin Edmund Kim},
  title = {Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer},
  journal = {Journal of Cancer Treatment and Research},
  volume = {3},
  number = {3},
  pages = {42-46},
  doi = {10.11648/j.jctr.20150303.14},
  url = {https://doi.org/10.11648/j.jctr.20150303.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20150303.14},
  abstract = {Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of angiogenesis by deoxypodophyllotoxin element as well as c-Met signal pathway inhibition in the pancreatic cancer. We present its therapeutic effect in 50 patients with stage IV pancreatic cancer for the first time in Korea. Materials and Methods From March 2013 to May 2014, there were 50 patients with stage IV pancreatic cancers admitted to Sahmyook Seoul Hospital for SB anticancer treatments with 24 control patient who did not get SB anticancer treatments in the same time interval.SB anticancer drug were administrated directly intratumoral injections using radiofrequent ablation techniques by interventional radiologist and intravenously by physician. Results Total 50 patients received SB anticancer therapy, male 25, female 25, and age ranged from 27 to 86 years with median age of 57 years with liver, lung, peritoneum and/or bone metastases, Control 24 patients, male 10, female 14, age ranged from 36 to 90 years with median age of 69 years. There was no significant side effect clinically as well as by laboratory measurement after every SB injections. Number of survived patients in SB study group was 27cases (54.0%), but only 2 cases(8.3%) in SB not treated control group ( p<0.01 with statistical significance). The total survival duration after diagnosis in SB treated group was 7 months, but 4 months in SB not treated control group. The interval from initial diagnosis to SB treatment in survived group was 2 month, less than 1 month in 12(44.4%) patients while in death group 5 months, and less than 1 month in only 3(14.3%) cases (p< 0.01 with statistical significance).The follow up duration and progression free estimate after SB treatment in survived group was median 5 months each, while in control group, median 2 months. Conclusion: SB natural anticancer drug administration is safe and increases survival rate and duration compared with control group, especially when treated within 1 month after diagnosis of stage IV pancreatic cancer. Long term follow up study with more numbers of patients are needed for accurate efficacy of SB treatment for advanced pancreatic cancer.},
 year = {2015}
}

Copy | Download

TY  - JOUR
T1  - Therapeutic Effects of SB Natural Anticancer Drug in 50 Patients with Stage IV Pancreatic Cancer
AU  - Kweon Sang Moon
AU  - Joo Yeon Ji
AU  - Yoo Jin Cho
AU  - Jong Hwa Lee
AU  - Myung Sup Choi
AU  - Euishin Edmund Kim
Y1  - 2015/07/04
PY  - 2015
N1  - https://doi.org/10.11648/j.jctr.20150303.14
DO  - 10.11648/j.jctr.20150303.14
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 42
EP  - 46
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20150303.14
AB  - Purpose: Pancreatic cancers are still difficult in early dection and progression is rapid that can be hardly cured. Surgical therapy is limited by its hypervascularity, poor responses of radiational therapy and anticancer drugs. Root extract of Pulsatilla Koreana, SB365 has shown apoptotic effect by Pulsatilla saponin D component, and inhibition of angiogenesis by deoxypodophyllotoxin element as well as c-Met signal pathway inhibition in the pancreatic cancer. We present its therapeutic effect in 50 patients with stage IV pancreatic cancer for the first time in Korea. Materials and Methods From March 2013 to May 2014, there were 50 patients with stage IV pancreatic cancers admitted to Sahmyook Seoul Hospital for SB anticancer treatments with 24 control patient who did not get SB anticancer treatments in the same time interval.SB anticancer drug were administrated directly intratumoral injections using radiofrequent ablation techniques by interventional radiologist and intravenously by physician. Results Total 50 patients received SB anticancer therapy, male 25, female 25, and age ranged from 27 to 86 years with median age of 57 years with liver, lung, peritoneum and/or bone metastases, Control 24 patients, male 10, female 14, age ranged from 36 to 90 years with median age of 69 years. There was no significant side effect clinically as well as by laboratory measurement after every SB injections. Number of survived patients in SB study group was 27cases (54.0%), but only 2 cases(8.3%) in SB not treated control group ( p<0.01 with statistical significance). The total survival duration after diagnosis in SB treated group was 7 months, but 4 months in SB not treated control group. The interval from initial diagnosis to SB treatment in survived group was 2 month, less than 1 month in 12(44.4%) patients while in death group 5 months, and less than 1 month in only 3(14.3%) cases (p< 0.01 with statistical significance).The follow up duration and progression free estimate after SB treatment in survived group was median 5 months each, while in control group, median 2 months. Conclusion: SB natural anticancer drug administration is safe and increases survival rate and duration compared with control group, especially when treated within 1 month after diagnosis of stage IV pancreatic cancer. Long term follow up study with more numbers of patients are needed for accurate efficacy of SB treatment for advanced pancreatic cancer.
VL  - 3
IS  - 3
ER  -

Copy | Download